<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5260">
  <stage>Registered</stage>
  <submitdate>19/07/2015</submitdate>
  <approvaldate>19/07/2015</approvaldate>
  <nctid>NCT02528188</nctid>
  <trial_identification>
    <studytitle>Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee</studytitle>
    <scientifictitle>A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-003721-22</secondaryid>
    <secondaryid>A4091058</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Pain</healthcondition>
    <healthcondition>Osteoarthritis, Hip</healthcondition>
    <healthcondition>Osteoarthritis, Knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - NSAID
Other interventions - Tanezumab 2.5 mg
Other interventions - Tanezumab 5 mg

Active Comparator: NSAID - Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks

Experimental: Tanezumab 2.5 mg - Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks

Experimental: Tanezumab 5 mg - Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks


Treatment: drugs: NSAID
Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks

Other interventions: Tanezumab 2.5 mg
Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks

Other interventions: Tanezumab 5 mg
Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of a predefined composite endpoint - Composite endpoint consists of adjudicated outcomes specified in protocol</outcome>
      <timepoint>80 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from Baseline in WOMAC Pain Subscale Score - Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale</outcome>
      <timepoint>Week 16</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from Baseline in WOMAC Physical Function Subscale Score - Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function subscale</outcome>
      <timepoint>Week 16</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from Baseline in Patient's Global Assessment of Osteoarthritis</outcome>
      <timepoint>Week 16</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of individual adjudication outcomes - Adjudication outcomes specified in protocol</outcome>
      <timepoint>80 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of all cause total joint replacements - All cause total joint replacement is as defined in the protocol</outcome>
      <timepoint>80 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Minimum Joint Space Width of the index knee - For subjects with Kellgren Lawrence Grade 2 or 3 osteoarthritis of the index knee</outcome>
      <timepoint>Weeks 56 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Minimum Joint Space Width of the index hip - For subjects with Kellgren Lawrence Grade 2 or 3 osteoarthritis of the index hip</outcome>
      <timepoint>Weeks 56 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of subjects with progression of osteoarthritis in the index knee according to Bland and Altman method - For subjects with Kellgren Lawrence Grade 2 or 3 osteoarthritis of the index knee</outcome>
      <timepoint>Weeks 56 and 80 (separately)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of subjects with progression of osteoarthritis in the index hip according to Bland and Altman method - For subjects with Kellgren Lawrence Grade 2 or 3 osteoarthritis of the index hip</outcome>
      <timepoint>Weeks 56 and 80 (separately)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC Pain subscale change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC Physical Function subscale change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient's Global Assessment of Osteoarthritis change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 16 (Japan only), 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>OMERACT OARSI responder index</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response: Reduction in the WOMAC Pain subscale of 30%, 50%, 70% and 90%</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative distribution of percent change from Baseline in the WOMAC Pain subscale score - Endpoint for summary only</outcome>
      <timepoint>Weeks 16, 24, and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response: Reduction in the WOMAC Physical Function subscale of 30%, 50%, 70% and 90%.</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative distribution of percent change from Baseline in the WOMAC Physical Function subscale score - Endpoint for summary only</outcome>
      <timepoint>Weeks 16, 24, and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response: Improvement of 2 points in Patient's Global Assessment of Osteoarthritis</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average pain score in the index joint change from Baseline</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC Stiffness subscale change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC Average change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC Pain Subscale Item: Pain When Walking on a Flat Surface, change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC Pain Subscale Item: Pain When Going Up or Down Stairs, change from Baseline</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Work Productivity and Activity Impairment Questionnaire for Osteoarthritis (WPAI:OA) impairment scores change from Baseline</outcome>
      <timepoint>Weeks 16, 24, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EuroQol 5 Dimension (EQ 5D 5L) dimensions and overall health utility score</outcome>
      <timepoint>Baseline and Weeks 8, 16, 24, 40, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Satisfaction Questionnaire Medicine v.II (TSQM v.II) satisfaction with effectiveness, side effects and convenience, and overall satisfaction</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Reported Treatment Impact Assessment Modified (mPRTI)</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and Time to discontinuation due to Lack of Efficacy</outcome>
      <timepoint>56 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Rescue Medication Use</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amount of Rescue Medication Taken</outcome>
      <timepoint>Weeks 2, 4, 8 and 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Care Resource Utilization</outcome>
      <timepoint>Baseline and Weeks 64, and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lower Extremity Activity Scale: change from Baseline - All subjects</outcome>
      <timepoint>Weeks 4, 8, 16, 24, 56 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in average daily minutes of physical activity - A subset of subjects</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in average daily physical activity counts - A subset of subjects</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in average daily minutes of moderate to vigorous physical activity - A subset of subjects</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in average daily minutes of bouted (sustained) moderate to vigorous physical activity - A subset of subjects</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in average daily step count - A subset of subjects</outcome>
      <timepoint>Weeks 16 and 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Subjects with Adverse Events</outcome>
      <timepoint>80 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Orthostatic (supine/standing) blood pressure</outcome>
      <timepoint>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56, 64 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survey of Autonomic Symptom scores</outcome>
      <timepoint>Screening and Weeks 24, 56 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurologic examinations - Neuropathy Impairment Score [NIS]</outcome>
      <timepoint>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56, 64 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti tanezumab antibody levels</outcome>
      <timepoint>Baseline, Weeks 8, 16, 32, 48, 56 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Physical Examination Findings</outcome>
      <timepoint>Screening and Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Subjects with Clinical Laboratory Test Abnormalities - Hematology and blood chemistry values</outcome>
      <timepoint>Baseline, Weeks 16 and 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline Sitting Blood Pressure</outcome>
      <timepoint>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56, 64 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline Sitting Heart Rate</outcome>
      <timepoint>Baseline, Weeks 2, 4, 8, 16, 34, 32, 40, 48, 56, 64 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline 12-lead Electrocardiogram</outcome>
      <timepoint>Screening, Weeks 56 and 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Days of Rescue Medication Use</outcome>
      <timepoint>Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  A diagnosis of osteoarthritis of the index hip or knee based on American College of
             Rheumatology criteria with Kellgren Lawrence X ray Grade of 2 as diagnosed by the
             Central Reader

          -  Currently receiving a stable dose regimen of oral NSAID (naproxen, celecoxib,
             diclofenac, aceclofenac, loxoprofen, ibuprofen, meloxicam, nabumetone, sulindac or
             ketoprofen) as described in the protocol along with a history of insufficient pain
             relief from, inability to tolerate or contraindication to taking acetaminophen and,
             tramadol or opioid treatments. Subjects must also maintain a stabilized, protocol
             specified NSAID dose regimen for at least the final 2 or 3 weeks of the Screening
             period

          -  WOMAC Pain subscale score of at least 5 in the index knee or hip at Screening

          -  Be willing to discontinue all non study pain medications for osteoarthritis and not
             use prohibited pain medications throughout the duration of the study

          -  Female subjects of childbearing potential must agree to comply with protocol specified
             contraceptive requirements</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects exceeding protocol defined BMI or body weight limits

          -  History of other diseases specified in the protocol (eg, inflammatory joint diseases,
             crystalline diseases such as gout or pseudogout) that may involve the index joint and
             that could interfere with efficacy assessments

          -  Radiographic evidence of protocol specified bone or joint conditions in any screening
             radiograph as determined by the central radiology reviewer

          -  A history of osteonecrosis or osteoporotic fracture

          -  History of significant trauma or surgery to a knee, hip or shoulder within the
             previous year

          -  Planned surgical procedure during the duration of the study

          -  Presence of conditions (eg, fibromyaliga, radiculopathy) associated with moderate to
             severe pain that may confound assessments or self evaluation of osteoarthritis pain

          -  Signs or symptoms of carpal tunnel syndrome in the year prior to Screening

          -  Considered unfit for surgery based upon American Society of Anesthesiologists physical
             classification system for surgery grading, or subjects who would not be willing to
             undergo joint replacement surgery if required

          -  Contraindications to magnetic resonance imaging

          -  History of intolerance or hypersensitivity to the oral NSAID (naproxen, celecoxib or
             diclofenac) the subject could be randomized to receive or any of its excipients or
             existence of a medical condition or use of concomitant medication for which the use of
             this NSAID is contraindicated

          -  History of intolerance or hypersensitivity to acetaminophen or any of its excipients
             or existence of a medical condition or use of concomitant medication for which the use
             of acetaminophen is contraindicated

          -  Use of prohibited medications without the appropriate washout period prior to
             Screening or Initial Pain Assessment Period

          -  History of cancer within 5 years of Screening, except for cutaneous basal cell or
             squamous cell cancer resolved by excision

          -  Subjects with signs and symptoms of clinically significant cardiac disease as
             described in the protocol

          -  Diagnosis of a transient ischemic attack in the 6 months prior to Screening, diagnosis
             of stroke with residual deficits that would preclude completion of required study
             activities

          -  History, diagnosis, or signs and symptoms of clinically significant neurological
             disease such as but not limited to peripheral or autonomic neuropathy

          -  History, diagnosis, signs or symptoms of any clinically significant psychiatric
             disorder

          -  History of known alcohol, analgesic or drug abuse within 2 years of Screening

          -  Previous exposure to exogenous NGF or to an anti-NGF antibody

          -  History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal
             antibody or IgG fusion protein

          -  Poorly controlled hypertension as defined in the protocol or taking an
             antihypertensive that has not been stable for at least 1 month prior to Screening

          -  Evidence of protocol defined orthostatic hypotension at Screening

          -  Disqualifying score on the Survey of Autonomic Symptoms questionnaire at Screening

          -  Screening AST, ALT, serum creatinine or HbA1c values that exceed protocol defined
             limits

          -  Presence of drugs of abuse in screening urine toxicology panel

          -  Positive hepatitis B, hepatitis C or HIV test results indicative of current infection

          -  Participation in other investigational drug studies within protocol defined time
             limits

          -  Pregnant, breastfeeding or female subjects of childbearing potential who are unwilling
             or unable to follow protocol required contraceptive requirements

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that in the judgment of the investigator, would make the subject
             inappropriate for entry into this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3022</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Genesis Research Services - Broadmeadow</hospital>
    <hospital>Hunter Imaging Group - Cardiff</hospital>
    <hospital>Optimus Clinical Research Pty Ltd - Kogarah</hospital>
    <hospital>Southern Radiology - Miranda</hospital>
    <hospital>Royal Hospital for Women - Randwick</hospital>
    <hospital>Castlereagh Imaging - St Leonards</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Australian Clinical Research Network - Sydney</hospital>
    <hospital>Spectrum Medical Imaging - Sydney</hospital>
    <hospital>AusTrials Pty Ltd - Sherwood</hospital>
    <hospital>CMAX-a division of IDT Australia Limited - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital Pharmacy - Adelaide</hospital>
    <hospital>Bensons Radiology - North Adelaide</hospital>
    <hospital>Capital Radiology-Malvern - Melbourne</hospital>
    <hospital>Emeritus Research - Melbourne</hospital>
    <hospital>Capital Radiology-Clayton - Melbourne</hospital>
    <hospital>SKG Radiology Hollywood - Nedlands</hospital>
    <hospital>RK Will Pty Ltd - Victoria Park</hospital>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>2285 - Cardiff</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2228 - Miranda</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2035 - Sydney</postcode>
    <postcode>4075 - Sherwood</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3144 - Melbourne</postcode>
    <postcode>3145 - Melbourne</postcode>
    <postcode>3168 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6100 - Victoria Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Ruse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Antioquia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota Dc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Oita</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shimane</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tottori</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kumamoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Klaipeda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Siauliai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>BOP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Arequipa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>La Libertad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>NCR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Niska Banja</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Sad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Sabac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nove Mesto nad Vahom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Piestany</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernivtsi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odesa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ternopil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the long-term joint safety and efficacy (pain relief)
      of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory
      drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02528188</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>